Article

Severity determines intraoperative floppy iris syndrome management approach

A cataract surgeon who first identified intraoperative floppy iris syndrome (IFIS) and its association with tamsulosin describes several approaches to managing the surgical complication. The approach a surgeon uses will depend on the severity of IFIS, he says.

Key Points

Dr. Chang, clinical professor of ophthalmology at the University of California, San Francisco, and in private practice in Los Altos, CA, reviewed different strategies including the use of a viscoadaptive ophthalmic viscosurgical device (OVD), intracameral epinephrine, iris retractors, and pupil expansion devices.

"When considering the management of IFIS, we must recognize that there is a wide range of severity among different patients taking tamsulosin and other alpha blockers," he said. "This means that a technique that works beautifully on one patient may not work on the next, which is why it is helpful to be adept at multiple strategies that can be used individually or in combination."

He recounted a multicenter prospective study that included 167 eyes of patients taking tamsulosin and undergoing cataract surgery. In that study, nine out of 10 eyes had IFIS of at least mild severity, and three out of four eyes had moderate to severe IFIS.

Management strategies

The first approach that Dr. Chang described, use of a highly retentive and viscoadaptive OVD, such as 2.3% sodium hyaluronate (Healon 5, Advanced Medical Optics), provides expanded pupillary dilation in patients with moderate-sized pupils, as he demonstrated in a video of a mild case of IFIS. For this strategy to be successful, one must use lower aspiration flow and vacuum settings on phacoemulsification equipment and be reasonably experienced with using this OVD, he said.

"As more [OVD] exits the eye, the floppy iris will constrict, requiring additional replenishment," Dr. Chang said. "This technique works best with reasonably large pupils and with softer nuclei, where you do not need high vacuum to optimize holding power," he added.

Dr. Chang also presented a video case of a patient who had stopped taking tamsulosin 18 months previously. After capsulorrhexis was performed and the phaco tip was inserted, the iris immediately began to billow and prolapsed to the phaco incision. After intracameral epinephrine 1:4000 (mixing 0.2 ml of 1:1000 bisulfite-free epinephrine with 0.6 ml of balanced salt solution in a 3-ml syringe) was injected, the pupil quickly dilated wider. Just as impressively, he said, the iris became more rigid, without any tendency for billowing or prolapse, and the rest of the case proceeded without any difficulty.

"This is a wonderful rescue technique, because it is more difficult to safely place iris retractors following the capsulorrhexis and hydrodissection," Dr. Chang stated. "Intracameral epinephrine is well tolerated, and for patients taking alpha blockers, there is no harm in trying it intraoperatively. While it might not always dilate the pupil further, it will at least increase iris rigidity in many cases. You can always combine [the 2.3% sodium hyaluronate OVD] with epinephrine to widen the pupil further for the capsulorrhexis step."

Patients taking tamsulosin who have pupils that dilate very poorly usually will have severe IFIS, according to Dr. Chang. "In these cases, I go straight to mechanical devices, such as iris retractors," he said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.